What is HC Wainwright's Forecast for Celcuity Q1 Earnings?

Celcuity Inc. (NASDAQ:CELC - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Celcuity in a report issued on Monday, May 19th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($1.09) per share for the quarter. HC Wainwright has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity's Q2 2026 earnings at ($1.13) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($0.71) EPS, FY2028 earnings at $1.26 EPS and FY2029 earnings at $3.26 EPS.

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research note on Thursday, May 15th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $30.80.

Celcuity Stock Up 0.8%

Shares of CELC opened at $10.69 on Tuesday. Celcuity has a 52 week low of $7.58 and a 52 week high of $19.77. The firm has a market cap of $404.50 million, a P/E ratio of -4.10 and a beta of 0.56. The firm's 50-day simple moving average is $10.15 and its 200 day simple moving average is $11.61. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.09.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CELC. SG Americas Securities LLC grew its position in shares of Celcuity by 83.2% during the 4th quarter. SG Americas Securities LLC now owns 14,646 shares of the company's stock worth $192,000 after purchasing an additional 6,651 shares in the last quarter. Bleakley Financial Group LLC acquired a new position in shares of Celcuity during the 4th quarter worth approximately $146,000. Rhumbline Advisers grew its position in shares of Celcuity by 20.6% during the 4th quarter. Rhumbline Advisers now owns 38,755 shares of the company's stock worth $507,000 after purchasing an additional 6,625 shares in the last quarter. New York State Common Retirement Fund grew its position in shares of Celcuity by 14.9% during the 4th quarter. New York State Common Retirement Fund now owns 28,391 shares of the company's stock worth $372,000 after purchasing an additional 3,682 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Celcuity by 20.3% during the 4th quarter. Bank of New York Mellon Corp now owns 64,125 shares of the company's stock worth $839,000 after purchasing an additional 10,828 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.